To faciliate the change process, companies must educate MSLs and reps to stay out of the grant-submission process. The new roles and job description should reflect this new regulatory landscape.
Product managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial